Investorium.tv June 6 Webcast - Emerging Star Performers ASX:MMJ ASX:TTC ASX:IIL
Sydney, May 4, 2016 - (ABN Newswire) - At Sydney's Premier Jazz Venue on June 6th at the Basement, 5 companies will be presenting on high tech biotech.
MMJ Phytotech (ASX:MMJ) Medical Cannabis Delivery Systems
Mr. Andreas Gedeon, Dipl.-Paed. has been the Chief Executive Officer and Managing Director at MMJ Phytotech Limited since July 27, 2015. Mr. Gedeon serves as the President at MMJ Bioscience Inc. He was former Officer in the German Navy. As the founder of MMJ, Mr. Gedeon oversees the global expansion strategy of the MMJ group and is the designated Managing Director of MMJ/PYL post-merger.
Traditional Therapy Clinics - (ASX:TTC) Andrew Sneddon (TBC)
Traditional Therapy Clinics Limited is a franchisor and the owner of one of the largest chains(largest by number of clinics) of traditional therapeutic health and wellness clinics in China. It is a well established business with a strong growth profile, employing a repeatable and scalable business model. TTC has a highly recognised and respected brand, having received the prestigious Chinese Well-Known Trademark designation from the State Administration for Industry and Commerce. It operates within a strongly regulated industry sector of significant scale, which offers opportunity for further growth.
Innate Immunotherapeutics (ASX:IIL) Simon Wilkinson
Simon has been the Managing Director and Chief Executive Officer of Innate Immunotherapeutics since 2004. He has been a shareholder in the Company since its formation in 2000. Simon has overseen Innate's transition from being a public unlisted New Zealand company trialling a passive immunotherapeutic drug candidate for HIV to being a listed Australian company focused on addressing the significant and unmet need in progressive multiple sclerosis. Prior to his 15 years involvement in biotech, Simon spent 20 years in finance, banking and business management after training as an officer in the Royal New Zealand Navy.
To register to view the Webcast live, please visit: http://www.investorium.tv/viewevent.asp?lang=&eid=2050
About: Innate Immunotherapeutics Limited
Innate Immunotherapeutics Limited (ASX:IIL) is a medical biotechnology company with offices in Sydney (Australia) and Auckland (New Zealand). The Company has designed and manufactured a unique immunomodulator microparticle technology. This technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as Multiple Sclerosis. The same technology can be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.
About: Investorium.tv
Investorium.tv is a Video Streaming and Live Financial Industry Event featuring CEOs of Public Companies held at Premier Venues in New York, Vancouver and Sydney. Investorium.tv records and video streams the events on "state of the art" digital recording and webcasting equipment, making high definition broadcast quality productions available to Members and the professional investment community.About: MMJ PhytoTech Ltd
MMJ PhytoTech Limited (ASX:MMJ) (formerly PhytoTech Medical Limited) is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.
It’s United Greeneries subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. Satipharm has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.
Through its PhytoTech Therapeutics subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.
About: Traditional Therapy Clinics Ltd
Traditional Therapy Clinics Limited (ASX:TTC) is a franchisor and the owner of one of the largest chains (by number of clinics) of traditional therapeutic health and wellness clinics in China. It currently has 315 franchise licences granted (4 of which are to be acquired by TTC) and 11 owned clinics in operation. It is a well established business with a strong growth profile, employing a repeatable and scalable business model. TTC has a highly recognised and respected brand, having received the prestigious Chinese Well-Known Trademark designation from the State Administration for Industry and Commerce. It operates within a strongly regulated industry sector of significant scale, which offers opportunity for further growth.
MMJ Phytotech (ASX:MMJ) Medical Cannabis Delivery Systems
Mr. Andreas Gedeon, Dipl.-Paed. has been the Chief Executive Officer and Managing Director at MMJ Phytotech Limited since July 27, 2015. Mr. Gedeon serves as the President at MMJ Bioscience Inc. He was former Officer in the German Navy. As the founder of MMJ, Mr. Gedeon oversees the global expansion strategy of the MMJ group and is the designated Managing Director of MMJ/PYL post-merger.
Traditional Therapy Clinics - (ASX:TTC) Andrew Sneddon (TBC)
Traditional Therapy Clinics Limited is a franchisor and the owner of one of the largest chains(largest by number of clinics) of traditional therapeutic health and wellness clinics in China. It is a well established business with a strong growth profile, employing a repeatable and scalable business model. TTC has a highly recognised and respected brand, having received the prestigious Chinese Well-Known Trademark designation from the State Administration for Industry and Commerce. It operates within a strongly regulated industry sector of significant scale, which offers opportunity for further growth.
Innate Immunotherapeutics (ASX:IIL) Simon Wilkinson
Simon has been the Managing Director and Chief Executive Officer of Innate Immunotherapeutics since 2004. He has been a shareholder in the Company since its formation in 2000. Simon has overseen Innate's transition from being a public unlisted New Zealand company trialling a passive immunotherapeutic drug candidate for HIV to being a listed Australian company focused on addressing the significant and unmet need in progressive multiple sclerosis. Prior to his 15 years involvement in biotech, Simon spent 20 years in finance, banking and business management after training as an officer in the Royal New Zealand Navy.
To register to view the Webcast live, please visit: http://www.investorium.tv/viewevent.asp?lang=&eid=2050
About: Innate Immunotherapeutics Limited
Innate Immunotherapeutics Limited (ASX:IIL) is a medical biotechnology company with offices in Sydney (Australia) and Auckland (New Zealand). The Company has designed and manufactured a unique immunomodulator microparticle technology. This technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as Multiple Sclerosis. The same technology can be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.
About: Investorium.tv
Investorium.tv is a Video Streaming and Live Financial Industry Event featuring CEOs of Public Companies held at Premier Venues in New York, Vancouver and Sydney. Investorium.tv records and video streams the events on "state of the art" digital recording and webcasting equipment, making high definition broadcast quality productions available to Members and the professional investment community.About: MMJ PhytoTech Ltd
MMJ PhytoTech Limited (ASX:MMJ) (formerly PhytoTech Medical Limited) is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.
It’s United Greeneries subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. Satipharm has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.
Through its PhytoTech Therapeutics subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.
About: Traditional Therapy Clinics Ltd
Traditional Therapy Clinics Limited (ASX:TTC) is a franchisor and the owner of one of the largest chains (by number of clinics) of traditional therapeutic health and wellness clinics in China. It currently has 315 franchise licences granted (4 of which are to be acquired by TTC) and 11 owned clinics in operation. It is a well established business with a strong growth profile, employing a repeatable and scalable business model. TTC has a highly recognised and respected brand, having received the prestigious Chinese Well-Known Trademark designation from the State Administration for Industry and Commerce. It operates within a strongly regulated industry sector of significant scale, which offers opportunity for further growth.